Date published: 2026-4-5

1-800-457-3801

SCBT Portrait Logo
Seach Input

eIF2α Inhibitors

Eukaryotic translation initiation factor 2 alpha (eIF2α) inhibitors represent a diverse class of chemical compounds that play a pivotal role in the regulation of protein synthesis within cells. These inhibitors target the phosphorylation status of eIF2α, a critical component of the translation initiation machinery. eIF2α is a key regulator of protein synthesis, acting as a switch that controls the flow of genetic information from messenger RNA (mRNA) to protein. Under normal conditions, eIF2α facilitates the formation of the translation initiation complex, enabling the ribosome to start protein synthesis. However, when cells encounter various stressors, such as endoplasmic reticulum (ER) stress, oxidative stress, or viral infections, eIF2α undergoes phosphorylation at a specific serine residue, leading to a translational halt as part of the integrated stress response (ISR). This phosphorylation event reduces the availability of active eIF2α, limiting global protein synthesis and allowing the cell to adapt to stressful conditions.

The class of eIF2α inhibitors includes various small molecules and compounds with distinct mechanisms of action. Some inhibitors directly target the kinases responsible for phosphorylating eIF2α, such as PERK (Protein kinase RNA-like endoplasmic reticulum kinase) or GCN2 (general control nonderepressible 2). By inhibiting these kinases, these compounds prevent eIF2α phosphorylation and restore normal translation initiation, effectively counteracting the cellular response to stress. Others, like ISRIB (Integrated Stress Response Inhibitor), work by enhancing the activity of eIF2B, the guanine nucleotide exchange factor responsible for converting inactive eIF2α into its active form. This augmentation of eIF2B activity promotes efficient translation initiation even in the presence of phosphorylated eIF2α. Additionally, compounds like guanabenz and salubrinal function by modulating the eIF2α phosphatase PP1 (protein phosphatase 1), which is responsible for reversing eIF2α phosphorylation.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Salubrinal

405060-95-9sc-202332
sc-202332A
1 mg
5 mg
$34.00
$104.00
87
(2)

Salubrinal inhibits eIF2α dephosphorylation, leading to prolonged phosphorylation, which reduces translation initiation.

ISRIB

1597403-47-8sc-488404
10 mg
$300.00
1
(0)

ISRIB enhances eIF2B activity, promoting the translation initiation process, counteracting eIF2α phosphorylation effects.

Guanabenz HCl

23113-43-1sc-507500
100 mg
$246.00
(0)

Guanabenz reduces eIF2α phosphorylation by activating the eIF2α phosphatase, PP1, allowing translation to proceed normally.

Eeyarestatin I

412960-54-4sc-358130B
sc-358130
sc-358130A
sc-358130C
sc-358130D
sc-358130E
5 mg
10 mg
25 mg
50 mg
100 mg
500 mg
$114.00
$203.00
$354.00
$697.00
$1363.00
$5836.00
12
(1)

Eeyarestatin I inhibits eIF2α dephosphorylation, leading to sustained phosphorylation and decreased protein synthesis.

GSK 2606414

1337531-36-8sc-490182
sc-490182A
5 mg
25 mg
$163.00
$572.00
(0)

GSK2606414 inhibits the activity of PERK, a kinase that phosphorylates eIF2α, reducing eIF2α phosphorylation levels.

Sephin1

13098-73-2sc-507502
5 mg
$578.00
(0)

Sephin1 selectively inhibits the eIF2α phosphatase, GADD34, preventing eIF2α dephosphorylation and reducing translation.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$138.00
$380.00
101
(4)

Cisplatin indirectly affects eIF2α by causing DNA damage, triggering the integrated stress response and eIF2α phosphorylation.